Wugen
Keith Vendola, MD, MBA, currently serves as the Chief Financial Officer at Wugen, a leading clinical-stage biotech company specializing in off-the-shelf allogeneic cell therapies. Vendola has a strong track record in the biotech sector, having held CFO roles at IO Biotech, where the company went public on Nasdaq, and Rezolute, which also achieved a successful public listing. Additionally, Vendola was instrumental in the IPO of Coherus BioSciences and has extensive experience in corporate development and strategy from positions at various biotech firms. Educational credentials include an MBA in Finance from Northwestern University, an MD from the Geisel School of Medicine at Dartmouth, and additional advanced training in negotiations and endocrinology.
This person is not in any offices
Wugen
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.